RYANODINE RECEPTOR INHIBITORS AND METHODS RELATING THERETO

摘要

The present invention provides novel ryanodine receptor type 2 (RyR2) inhibitors and methods of their use in the treatment of cardiac conditions. In general, the RyR2 inhibitors of the present invention assist in the normalization of intracellular calcium homeostasis. In certain embodiments, the RyR2 inhibitors are store-overload-induced Ca²⁺ release (SOICR) inhibitors that minimally inhibit or do not inhibit Ca²⁺-induced Ca²⁺ release (CICR), thereby providing beneficial effects in cardiac therapy.